Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.78B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.60M
Average 1.11M
AGIO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Agios Pharmaceuticals, Inc.NASDAQ: AGIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $99.11M (cash outflow) rose 11.0% year over year, ahead of the -163.5% change in trailing-twelve-month net income. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at +21.2% a year.
Context
- Net income amounted to 764.0% of revenue in FY2025, down 1081.9 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$330.94M (-19.8%) for the fiscal year ending Dec 2026, a step up from the -161.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$99.11M-8.3% QoQ
- Last fiscal yearDec 2025
- -$412.78M-161.3% YoY
- LTMMar 2026
- -$422.6M-163.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.0% | -11.8% | -22.8 pp |
| 1 year | -161.3% | -19.8% | +141.4 pp |
| 3-year CAGR | +21.2% | -40.9% | -62.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (412.78M) USD
- Year-over-year change
- -161.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (412.78M) | -161.3% |
| FY2024 | 2024-12-31 | 673.73M | +291.4% |
| FY2023 | 2023-12-31 | (352.09M) | -51.9% |
| FY2022 | 2022-12-31 | (231.8M) | +35.0% |
| FY2021 | 2021-12-31 | (356.51M) | — |
Net Income vs competitors
How AGIO compares with its peers on the latest reported figures
- AGIO's LTM Mar 2026 net income of $422.6M is the 3rd largest of the 7 companies compared; the peer median is $255.68M.
- Its year-over-year change of -163.5% is the lowest of 7, against a peer median of +166.5%.
- Net income amounts to 639.8% of revenue for AGIO, versus a peer median of 28.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.65B | +2718.1% | -44.4% | 267.0% | |
| LTM Mar 2026 | $608.92M | +10.8% | -6.7% | 91.0% | |
| LTM Mar 2026 | $422.6M | -163.5% | +21.2% | 639.8% | |
| LTM Jun 2026 | $268.25M | +651.2% | — | 28.5% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $243.1M | +34.2% | +65.5% | — |
| LTM Jun 2026 | $38.38M | -106.1% | — | 3.8% | |
| LTM Mar 2026 | $14.61M | +298.9% | -42.4% | 4.0% | |
| Peer median (excluding AGIO) | $255.68M | +166.5% | -24.6% | 28.5% | |
Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (356.51M) | (231.8M) | (352.09M) | 673.73M | (412.78M) |
| Depreciation & Amortization | 9.24M | 8.56M | 6.62M | 5.65M | 5.18M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 53.51M | 49.3M | 44.77M | 42.85M | 52.55M |
| Change in Working Capital | (36.82M) | (16.43M) | (19.06M) | (19.77M) | (33.04M) |
| Accounts Receivables | (4.38M) | (2.21M) | (604K) | (1.3M) | (6.47M) |
| Inventory | 0 | (8.49M) | (10.58M) | (8.54M) | (5.3M) |
| Accounts Payables | 1.86M | 3.44M | (8.73M) | 6.6M | 1.75M |
| Other Working Capital | (34.31M) | (9.17M) | 864K | (16.53M) | (23.02M) |
| Other Non-Cash Items | (76.74M) | (119.1M) | 23.69M | (1.09B) | 15.12M |
| Operating Cash Flow | (407.32M) | (309.48M) | (296.06M) | (389.84M) | (372.98M) |
| Capital Expenditures | (5.74M) | (4.88M) | (999K) | (1.69M) | (4.32M) |
| Acquisitions (Net) | 0 | 132.75M | 0 | 40K | 0 |
| Purchases of Investments | (1.38B) | (1.03B) | (417.93M) | (1.54B) | (641.76M) |
| Sales of Investments | 829.8M | 1.15B | 674.68M | 818.38M | 1.03B |
| Other Investing Activities | 1.8B | 0 | (16.18M) | 1.09B | (10M) |
| Investing Cash Flow | 1.25B | 243.26M | 239.58M | 363.44M | 377.18M |
| Debt Repayment | (578K) | (331K) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 2.68M | 5.43M | 14.44M | 8.68M |
| Common Stock Repurchased | (802.49M) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.3M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | (765.77M) | 2.35M | 5.43M | 14.44M | 8.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 75.69M | (63.87M) | (51.05M) | (11.96M) | 12.88M |
| Free Cash Flow | (413.06M) | (314.36M) | (297.06M) | (391.53M) | (377.29M) |
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.